Clear Creek Bio
Clear Creek Bio is a private biotech company focused on developing novel therapies for infectious diseases and cancer, with a mission to rapidly develop safe, effective, and easy-to-administer therapeutics. The company specializes in host-targeting and direct-acting small molecules, with a focus on antiviral and oncology therapeutics, including COVID-19 treatments.
Industries
Nr. of Employees
small (1-50)
Clear Creek Bio
585 Massachusetts Avenue, Cambridge, MA 02139
Patents
Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
US-12076315-B2
View Details
Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
US-12076315-B2
View DetailsProducts
Brequinar (DHODH inhibitor) — clinical-stage small-molecule candidate
Orally available small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) designed to deplete host pyrimidine pools, inhibit viral RNA synthesis, and be used as a broad-spectrum antiviral; evaluated in Phase 1 and Phase 2 clinical studies for SARS-CoV-2 and investigated for oncology (AML).
PLpro inhibitor program (oral direct-acting antiviral candidates)
Discovery-stage program producing potent inhibitors of the SARS-CoV-2 papain-like protease (PLpro) with the goal of developing orally available direct-acting antivirals; program progressed under cooperative agreements with NCATS/NIH and through a research and license collaboration with a pharmaceutical partner.
Brequinar (DHODH inhibitor) — clinical-stage small-molecule candidate
Orally available small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) designed to deplete host pyrimidine pools, inhibit viral RNA synthesis, and be used as a broad-spectrum antiviral; evaluated in Phase 1 and Phase 2 clinical studies for SARS-CoV-2 and investigated for oncology (AML).
PLpro inhibitor program (oral direct-acting antiviral candidates)
Discovery-stage program producing potent inhibitors of the SARS-CoV-2 papain-like protease (PLpro) with the goal of developing orally available direct-acting antivirals; program progressed under cooperative agreements with NCATS/NIH and through a research and license collaboration with a pharmaceutical partner.
Services
Research collaborations, cooperative research agreements, and exclusive licensing arrangements to advance discovery programs and transition candidates to partner-led development.
Research collaborations, cooperative research agreements, and exclusive licensing arrangements to advance discovery programs and transition candidates to partner-led development.
Expertise Areas
- Small-molecule drug discovery
- Antiviral therapeutics development
- Host-targeted therapeutics (DHODH inhibition)
- Protease-targeted inhibitor development
Key Technologies
- Small-molecule medicinal chemistry
- Enzyme-targeted inhibitor design
- Cell-based antiviral assays
- In vivo infectious disease models
News & Updates
The company announced dosing the first patient in a Phase 2 clinical trial evaluating brequinar for COVID-19 treatment, assessing antiviral activity, safety, and tolerability.
Clear Creek Bio Doses First Patient in Clinical Study of Brequinar in Hospitalized COVID-19 Patients
The company received FDA clearance for an IND and dosed the first patient in a Phase 1 study of brequinar for COVID-19, targeting broad-spectrum antiviral activity.
The collaboration aims to develop inhibitors of the SARS-CoV-2 PLpro enzyme for COVID-19 treatment, expanding Pfizer’s antiviral pipeline.
An article discussing brequinar's potential as an oral COVID-19 treatment and its combination with other antivirals.
An article emphasizing the need for medicines for COVID-19, highlighting Clear Creek Bio's efforts.
The company announced dosing the first patient in a Phase 2 clinical trial evaluating brequinar for COVID-19 treatment, assessing antiviral activity, safety, and tolerability.
Clear Creek Bio Doses First Patient in Clinical Study of Brequinar in Hospitalized COVID-19 Patients
The company received FDA clearance for an IND and dosed the first patient in a Phase 1 study of brequinar for COVID-19, targeting broad-spectrum antiviral activity.
The collaboration aims to develop inhibitors of the SARS-CoV-2 PLpro enzyme for COVID-19 treatment, expanding Pfizer’s antiviral pipeline.
An article discussing brequinar's potential as an oral COVID-19 treatment and its combination with other antivirals.
An article emphasizing the need for medicines for COVID-19, highlighting Clear Creek Bio's efforts.